Head-to-head · WeighScore
Get Thin MD vs Omada Health
The verdict
Get Thin MD takes it — 66.7/100 to 55.6/100.
Get Thin MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Get Thin MD is a nationwide async telehealth platform offering compounded semaglutide and tirzepatide injections plus brand-name Ozempic and Zepbound where appropriate, alongside a broader wellness menu…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Get Thin MD | Omada Health |
|---|---|---|
| WeighScore | 66.7/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #185 | #436 |
| Semaglutide | $199/mo (compounded) | Not disclosed |
| Tirzepatide | $299/mo (compounded) | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #185 · C
Strengths
- 3-month compounded semaglutide at $169/mo is among the lowest ongoing prices in the category
- Price-lock promise — same price every dose, no hidden fees
- Both compounded and brand-name options on one platform (sema, tirz, plus Ozempic and Zepbound)
- Nationwide availability with async evaluation — no in-person visit
- Broader wellness menu (sermorelin, NAD+, HRT, hair loss) lets you consolidate protocols
Where it loses points
- Compounded medications aren't FDA-approved and lack the review of brand-name GLP-1s
- Pharmacy partners not named — no way to verify the compounding source or batch testing
- Claims nationwide coverage but publishes no state list — confirm at intake
- Headline results (9.6 lbs in 30 days) come from self-reported patient data, not a trial
- Wide wellness funnel may steer you toward non-weight-loss protocols
Graded #436 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.